title: Clinical Indications and Adverse Reactions of Platelet Apheresis.
abstract: OBJECTIVE
  To determine the clinical indications and adverse reactions of platelet apheresis procedure.
  
  
  METHODS
  Cross-sectional, observational study.
  
  
  METHODS
  Blood Bank of Pakistan Atomic Energy Commission General Hospital, Islamabad, from January 2010 to December 2014.
  
  
  METHODS
  Indications and adverse reaction verified for 200 consecutive platelet apheresis donations performed for 125 patients was included in this study. Data was analysed for descriptive variables using SPSS version 16.
  
  
  RESULTS
  Donor deferral rate in the study was 63.83%. All the donors were males (100%) and replacement donors. Most prevalent blood type was B-positive (n=63, 31.5%), followed by O-positive (n=59, 29.5%). Rh negative groups constituted 13.5% (n=27) of all the donors. Average age of platelet apheresis donors was 28.56 ± 5.77 years. Maximum numbers of donors were in age range 20 - 30 years. Average weight of the donors was 73.96 ± 11.96 kg. Mean pre-procedure platelet count of donors was 268,000/µL. The postprocedure average platelet count was approximately 200,000/µL. The mean duration of a platelet apheresis session was 78.27 ± 26.07 minutes. Average volume of the final product was 412.53 ± 45.33 ml. Average volume of anti-coagulant acid citrate dextrose used per procedure was 300 ± 40 ml, 245 ml returned to donor along with returned blood while 55 ml used as anticoagulant in final concentrate. Of total 200, two (1%) final products were contaminated with red cells. Three (1.5%) products were not issued and finally expired. Of the 125 patients for which plateletpheresis procedures were performed, 54 (43.2%) patients were males and 71 (56.8%) were females (M: F=0.76:1). Six donors (3%) had adverse events: three donors (1.5%) had mild reactions, two (1%) moderate reaction, and one donor (0.5%) developing hematoma. None had severe or life-threatening reactions.
  
  
  CONCLUSIONS
  Plateletpheresis procedure is relatively safe and forms an important adjuvant to blood bank inventory.
authors.affiliation: Department of Pathology, Pakistan Atomic Energy Commission General Hospital, Islamabad.
authors.forename: Samina Tufail
authors.initials: ST
authors.lastname: Amanat
authors.affiliation: Department of Pathology, Pakistan Atomic Energy Commission General Hospital, Islamabad.
authors.forename: Huma Abdul
authors.initials: HA
authors.lastname: Shakoor
authors.affiliation: Department of Pathology, Pakistan Atomic Energy Commission General Hospital, Islamabad.
authors.forename: Masooma
authors.initials: M
authors.lastname: Raza
authors.affiliation: Department of Blood Bank, Pakistan Atomic Energy Commission General Hospital, Islamabad.
authors.forename: Nadeem
authors.initials: N
authors.lastname: Khan
authors.affiliation: Department of Blood Bank, Pakistan Atomic Energy Commission General Hospital, Islamabad.
authors.forename: Abdul
authors.initials: A
authors.lastname: Rauf
mesh_terms: D000293:Adolescent; D000328:Adult; D001771:Blood Banks; D001782:Blood Donors; D003430:Cross-Sectional Studies; D005260:Female; D006406:Hematoma / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010154:Pakistan / Q000453:epidemiology; D010983:Plateletpheresis / Q000009:adverse effects*; D015995:Prevalence; D019462:Syncope, Vasovagal / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D013997:Time Factors; D055815:Young Adult